Q2 beat reinforces the investment story; diversification efforts remain on course
07/08/26 -"Genmab’s Q2 performance exceeded expectations. The blood cancer drug Darzalex demonstrated strong results, with other drugs also showing solid growth. Profitability improved and 2026 guidance ..."
Pages
50
Language
English
Published on
07/08/26
You may also be interested by these reports :
07/08/26
Genmab’s Q2 performance exceeded expectations. The blood cancer drug Darzalex demonstrated strong results, with other drugs also showing solid ...
05/08/26
The Q2 results exceeded expectations, aided by sustained strong uptake for the Wegovy pill (obesity). Consequently, the management upgraded its ...
04/08/26
BioNTech reported a disappointing quarter, with sales significantly below forecasts and operating losses exceeding expectations. Weaker Covid-19 ...
04/08/26
Imagine a restaurant having to serve its customers by ordering outside food. We cannot resist drawing parallels between this hypothetical scenario ...